Explosion Sensitizer Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well []
Wo verlaufen die Gleitenden Durchschnitte? Die 200-Tage-Linie (GD200) der Luminex verläuft aktuell bei 29,45 USD. Damit erhält die Aktie die Einstufung Buy, insofern der Aktienkurs selbst bei 36,8 USD aus dem Handel ging und damit einen Abstand von +24,96 Prozent aufgebaut hat. Anders ist das Verhältnis gegenüber dem gleitenden Durchschnittskurs der zurückliegenden 50 Tage. Der GD50 hat derzeit ein Niveau von 36,77 USD angenommen. Dies wiederum entspricht für die Luminex-Aktie der aktuellen Differenz von +0,08 Prozent und damit einem Hold-Signal. Der Gesamtbefund auf Basis der beiden Zeiträume lautet demnach Buy. Wie schlägt sich Luminex bei der Dividende? Aus der gezahlten Dividende und dem jeweiligen Kurs errechnet sich die Dividendenrendite. Luminex weist derzeit eine Dividendenrendite von 1,09 % aus. Diese Rendite ist nur leicht niedriger als der Branchendurchschnitt (Life Sciences Werkzeuge und Dienstleistungen) von 1,56 %. Mit einer Differenz von lediglich 0,47 Prozentpunkten ergibt sich daraus die Einstufung als Hold bezüglich der ausgeschütteten Dividende.
→ Google Translate
Precision Business Insights published a research report on "Global Flow Cytometry Market: By Technology (Bead Based, Cell Based) By Products (Software, Instrument, Services, Accessories), By Applications (Research and Development, Industrial, Clinical Trials and Clinical Practice, Diagnosis), By end user (Hospitals,
NEW YORK , June 7, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16 th Floor New York , NY 10036 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Luminex Corporation Full story available on Benzinga.com
DBMR published a research report on Influenza Testing Market 2021 Industry Analysis, Size, Share, Growth, Trends and Forecast to 2027. Influenza Testing Market report provides analysis of top players in all regions with industry size, growth, technology, market insights, demand,
The Latest research study released by CMI "Global Proteomics Market" with 360+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, opportunities, market viewpoint
A Latest intelligence report published by AMA Research with title Drug Discovery Technologies Market Outlook to 2025.A detailed study accumulated to offer Latest insights about acute features of the Global Drug Discovery []
Blood testing is crucial for the diagnosis of various chronic diseases such as cancer, HIV/AIDS, diabetes, anemia and coronary heart disease. It is one the routine examinations and does not require special preparation. There are various types of blood test
AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the
Luminex Corporation announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021.
Related Stocks: LMNX ,
https://www.investing.com/news/stock-market-news/luminex-jumps-on-18-billion-deal-from-italys-diasorin-2472041
Italian diagnostics firm DiaSorin SpA (OTCMKTS: DSRLF) has agreed to acquire Luminex Corporation (NASDAQ: LMNX ) for $37 per share in an all-cash transaction, corresponding to a total equity value of approximately $1.8 billion. The offer price represents around 23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February (the date before press rumors regarding a potential sale of the company). Luminex makes COVID-19 laboratory tests along … Full story available on Benzinga.com
AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company's new multi-analyte respiratory panel combining Flu A/B and…
AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) that includes…
Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus targets with the SARS-CoV-2 target that can run on all ARIES Systems. These six and 12-cassette systems are automated molecular diagnostic… Read More »Luminex Secures BARDA Funding To Develop And Validate Flu/COVID-19 Combo Respiratory Panel
AUSTIN, Texas, Feb. 19, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and…
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT FINANCIAL…
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 per share of common stock payable on April 15, 2021 to stockholders of record as of the…
AUSTIN, Texas, Jan. 27, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter ended December 31, 2020 on Monday, February 8, 2021. A press release announcing the results is scheduled for release after the close of…
Cascas Discovery Highlights: Copper Anomaly Expansion of the soil copper anomaly to over 7 kms in length, remaining open in multiple directions. Discovery of high-grade porphyry copper mineralization in outcrop in northern sector (up to 1.1% Cu). New Gold Target (Kuru) Discovery of large…
AUSTIN, Texas, Jan. 12, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 2019 and full-year revenue of approximately $417M, up approximately 25% over the full year 2019….
AUSTIN, Texas, Dec. 16, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that Nachum "Homi" Shamir, Chairman, CEO and President, and Harriss Currie, Senior Vice President and CFO, will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held…
AUSTIN, Texas, Dec. 7, 2020 /PRNewswire/ -- On December 3, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors approved a $0.01 increase in the quarterly dividend, to $0.10 per share of common stock, payable on January 14, 2021 to stockholders of…
Flow cytometry is a laser-based or impedance-based biophysical technology employed in cell counting, cell sorting, biomarker detection, and protein engineering. The process is conducted by suspending cells in a stream of fluid and passing them through an electronic detection apparatus.
AUSTIN, Texas, Nov. 5, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its third quarter ended September 30, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT FINANCIAL HIGHLIGHTS…
To prepare market research report, certain steps are to be followed for collecting, recording and analysing market data. Imaging Flow Cytometer Equipment Market research report identifies and analyses the emerging trends along with major drivers, inhibitors, challenges and opportunities in
Highlights: High potential, underexplored copper-gold-molybdenum porphyry belt Extensive multi-kilometre geochemical and geophysical footprint Copper enrichment at surface, indicating potential for high copper grades VANCOUVER, BC, Oct. 22, 2020 /PRNewswire/ - Luminex Resources Corp….
Global flow cytometry market size is set to grow at a remarkable pace in the coming years, attributed to technological advancements and high adoption in various research and diagnostic applications. In addition, the advent of flow cytometry technology in novel
BidaskClub cut shares of Luminex (NASDAQ:LMNX) from a sell rating to a strong sell rating in a report published on Friday morning, BidAskClub reports. Several other brokerages have also recently weighed in on LMNX. Zacks Investment Research cut shares of Luminex from a buy rating to a hold rating and set a $26.00 price target […]
Analysts expect Luminex Co. (NASDAQ:LMNX) to announce $106.28 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Luminex’s earnings, with the highest sales estimate coming in at $106.90 million and the lowest estimate coming in at $105.35 million. Luminex posted sales of $78.67 million during the same quarter last […]
According to this study, over the next five years the Single Nucleotide Polymorphism (SNP) Genotyping market will register a 21.9%% CAGR in terms of revenue, the global market size will reach $ 24540 million by 2025, from $ 11120 million
AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response…
AUSTIN, Texas, Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response…
CINCINNATI--(BUSINESS WIRE)--Luminex Announces Scott Meader as CEO
VANCOUVER, BC, Aug. 18, 2020 /PRNewswire/ - Luminex Resources Corp. (TSXV: LR) (OTCQX: LUMIF) (the "Company" or "Luminex") is pleased to announce that its common shares are now trading on the OTCQX Best Market, a U.S. market operated by OTC Markets Group in New York, under the symbol…
Vaccine Execs Rake In $1 Billion In Stock Sales As Positive Headlines Boost Shares Tyler Durden Mon, 07/27/2020 - 15:13 With the race to find a vaccine for COVID-19 in full effect, biotech executives and other insiders from at least 11 companies have made hand over fist - raking in over $1 billion in stock sales after announcing positive developments, according to the New York Times . In some cases, company insiders are profiting from regularly scheduled compensation or automatic stock trades. But in other situations, senior officials appear to be pouncing on opportunities to cash out while their stock prices are sky high . And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. -NYT In May, we noted that insiders at Moderna cashed out on some $30 million in options - while CEO Stephane Bancel has become a billionaire. Moderna CEO Stéphane Bancel The company's market value is now nearly $30 billion thanks to a stream of positive press releases, while insiders have sold around $248 million altogether since January - most of it coming following an April announcement that the company had been selected to receive federal funding to support their efforts. 1/ It is good to be Stephane Bancel, CEO of Moderna.
AUSTIN, Texas, July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) to include the SARS-CoV-2 virus for high-throughput COVID-19 testing….
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020. A press release announcing the results is scheduled for release after the close of trading…
AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the company's xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. Clinical laboratories can now use this…
AUSTIN, Texas, July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019. Highlights include: Molecular Diagnostics revenue of approximately $65 million, up over…
AUSTIN, Texas, June 29, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug Administration (FDA) for its xMAP® SARS-CoV-2 Multi-Antigen IgG assay. The assay was developed to…
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex Corporation has been struggling lately, but the selling pressure may be coming to an end soon
Luminex (LMNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Luminex (LMNX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Zacks.com featured highlights include: Acacia, Virtu and Luminex
AUSTIN, Texas, May 8, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) ("Luminex") announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement pursuant to Section…
Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.
AUSTIN, Texas, May 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its first quarter ended March 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT HIGHLIGHTS Total revenue for…
- ← Previous
- 1
- 2
- Next →